Abbvie Inc (NYSE:ABBV)
| 149.10 Delayed Data As of Sep 29 |  -3.15 / -2.07%Today’s Change | 130.96 Today|||52-Week Range 168.11 | -7.74% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $269.6B |
Company Description
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
Contact Information
AbbVie, Inc. 1 North Waukegan Road North Chicago Illinois 60064-6400 |
Employees
Shareholders
| Mutual fund holders | 39.65% |
| Other institutional | 31.41% |
| Individual stakeholders | 0.16% |
Top Executives
| Richard A. Gonzalez | Chairman & Chief Executive Officer |
| Robert A. Michael | Vice Chairman, President & Chief Operating Officer |
| Scott T. Reents | Chief Financial Officer & Executive Vice President |
| Thomas J. Hudson | Chief Scientific Officer, Senior VP-R&D |
| Tim Richmond | Chief Human Resources Officer & Executive VP |